Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023.
van Leeuwen LP, Shamier MC, Verstrepen BE, Götz HM, Schmitz KS, Akhiyate N, Wijnans K, Bogers S, van Royen ME, van Gorp EC, Koopmans MP, de Vries RD, GeurtsvanKessel CH, Zaeck LM. van Leeuwen LP, et al. Among authors: zaeck lm. Euro Surveill. 2024 Sep;29(38):2400575. doi: 10.2807/1560-7917.ES.2024.29.38.2400575. Euro Surveill. 2024. PMID: 39301741 Free PMC article.
Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.
Fryer HA, Geers D, Gommers L, Zaeck LM, Tan NH, Jones-Freeman B, Goorhuis A, Postma DF, Visser LG, Hogarth PM, Koopmans MPG, GeurtsvanKessel CH, O'Hehir RE, van der Kuy PHM, de Vries RD, van Zelm MC. Fryer HA, et al. Among authors: zaeck lm. J Infect. 2024 Oct;89(4):106246. doi: 10.1016/j.jinf.2024.106246. Epub 2024 Aug 8. J Infect. 2024. PMID: 39127451 Free article.
Potential determinants of the decline in mpox cases in Belgium: A behavioral, epidemiological and seroprevalence study.
De Vos E, Van Gestel L, Brosius I, Kenyon C, Vuylsteke B, De Baetselier I, Mariën J, Bangwen E, Couvreur S, Lecompte A, Van Beckhoven D, Hoorelbeke B, Verstrepen BE, Zaeck LM, de Vries RD, Geurts van Kessel CH, Hens N, Ariën KK, Vercauteren K, Van Esbroek M, Van Dijck C, Liesenborghs L. De Vos E, et al. Among authors: zaeck lm. Int J Infect Dis. 2024 Sep;146:107132. doi: 10.1016/j.ijid.2024.107132. Epub 2024 Jun 26. Int J Infect Dis. 2024. PMID: 38942168 Free article.
Profiling the SARS-CoV-2-specific T-cell response.
Geers D, Gommers L, Tan NH, Bogers S, van Baarle D, Grifoni A, Sette A, Boerma A, Visscher F, Richard M, Funk M, Zaeck LM, van der Kuy PHM, Haagmans BL, Koopmans MP, GeurtsvanKessel CH, de Vries RD. Geers D, et al. Among authors: zaeck lm. Lancet Infect Dis. 2024 Aug;24(8):e477-e478. doi: 10.1016/S1473-3099(24)00377-3. Epub 2024 Jun 20. Lancet Infect Dis. 2024. PMID: 38909615 No abstract available.
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
Zaeck LM, Tan NH, Rietdijk WJR, Geers D, Sablerolles RSG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Rugebregt S, Goorhuis A, Postma DF, Visser LG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, Haagmans BL, van Baarle D, Koopmans MPG; SWITCH-ON Research Group; van der Kuy PHM, GeurtsvanKessel CH, de Vries RD. Zaeck LM, et al. Nat Commun. 2024 May 18;15(1):4224. doi: 10.1038/s41467-024-48414-x. Nat Commun. 2024. PMID: 38762522 Free PMC article. Clinical Trial.
Scenarios of future mpox outbreaks among men who have sex with men: a modelling study based on cross-sectional seroprevalence data from the Netherlands, 2022.
Shamier MC, Zaeck LM, Götz HM, Vieyra B, Verstrepen BE, Wijnans K, Welkers MR, Hoornenborg E, van Cleef BA, van Royen ME, Jonas KJ, Koopmans MP, de Vries RD, van de Vijver DA, GeurtsvanKessel CH. Shamier MC, et al. Among authors: zaeck lm. Euro Surveill. 2024 Apr;29(17):2300532. doi: 10.2807/1560-7917.ES.2024.29.17.2300532. Euro Surveill. 2024. PMID: 38666400 Free PMC article.
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH, Geers D, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Boerma A, Nijhof SH, van Dort KA, Koopmans MPG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, van Baarle D, Zaeck LM, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH ON Research Group. Tan NH, et al. Among authors: zaeck lm. Lancet Infect Dis. 2023 Aug;23(8):901-913. doi: 10.1016/S1473-3099(23)00140-8. Epub 2023 Apr 21. Lancet Infect Dis. 2023. PMID: 37088096 Free PMC article. Clinical Trial.
25 results